ABSORB III Trial: Two-year outcomes
Absorb everolimus-eluting bioresorbable vascular scaffold (BRS) vs. XIENCE stent? We join S. Ellis, the study’s lead author, as we examine our evolving understanding of BRS in this non-inferiority trial. What were the principal endpoints and results? What was the cause of an observed “increase in risk”? Did this impact the study results? What lessons have we learned? Vessel size? Technique? Join us as we examine a device which is still challenging, but increasingly understood…
This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).